Spectrum Pharmaceuticals Announces Three Poster Presentations at Upcoming San Antonio Breast Cancer Symposium
December 04 2020 - 7:00AM
Business Wire
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical
company focused on novel and targeted oncology therapies, today
announced that three posters highlighting its drug development
pipeline would be presented at the upcoming San Antonio Breast
Cancer Conference (SABCS) to be held December 8 – 11, 2020.
“We are pleased to have two scientific communications at SABCS
on ROLONTIS® (eflapegrastim) and the results of our Phase 2 study
for Poziotinib in HER2+ metastatic breast cancer who have failed
multiple lines of HER2 directed therapy,” said Francois Lebel,
M.D., Chief Medical Officer at Spectrum Pharmaceuticals. “We look
forward to sharing these data with the medical and scientific
community.”
The three posters are listed below.
Poster Title: A Phase 2 study of poziotinib in patients
with HER2-positive metastatic breast cancer previously treated with
HER2 therapies Authors: Adam Brufsky, M.D., Ph.D., et al.
Poster Number: PD1-07 (Spotlight Poster Discussion)
Poster Category: Breast Cancer treatment Poster
Section: Spotlight Poster Discussion 1 Poster Presentation
Date/Time: December 9, 2020 4:00 PM – 5:15 PM CT
Poster Title: Pooled efficacy analysis from two Phase 3
studies in patients receiving eflapegrastim, a novel, long-acting
granulocyte-colony stimulating factor, following TC for early stage
breast cancer Authors: Lee S. Schwartzberg, M.D., et al.
Poster Number: PS9-59 Poster Category: Psychosocial,
Quality of Life and Educational Aspects Poster Section:
Poster Session 9 Poster Presentation Date/Time: Wednesday,
December 9, 2020: 8:00 AM CT.
Poster Title: Open-label, Phase 1 study to evaluate
duration of severe neutropenia after the same-day, varying dosing
time schedules of eflapegrastim administration in patients with
breast cancer receiving docetaxel and cyclophosphamide
(NCT04187898) Authors: Lee S. Schwartzberg, M.D., et al.
Poster Number: OT-06-01 Poster Category: Chemotherapy
- Targeting Neutropenia Poster Section: Ongoing Trial
posters Poster Presentation Date/Time: Wednesday, December
9, 2020: 8:00 AM CT
Copies of the posters will be available on the Spectrum
Pharmaceuticals website following presentation at the meeting.
ROLONTIS is an investigational drug not approved by the U.S. Food
and Drug Administration (FDA) and the BLA is currently under review
by the agency for the treatment of chemotherapy-induced
neutropenia.
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals is a biopharmaceutical company focused
on acquiring, developing, and commercializing novel and targeted
oncology therapies. Spectrum has a strong track record of
successfully executing across the biopharmaceutical business model,
from in-licensing and acquiring differentiated drugs, clinically
developing novel assets, successfully gaining regulatory approvals
and commercializing in a competitive healthcare marketplace.
Spectrum has a late-stage pipeline with novel assets that serve
areas of unmet need. This pipeline has the potential to transform
the company in the near future. For additional information on
Spectrum Pharmaceuticals, please visit www.sppirx.com.
Forward-looking statement — This press release may contain
forward-looking statements regarding future events and the future
performance of Spectrum Pharmaceuticals that involve risks and
uncertainties that could cause actual results to differ materially.
These statements are based on management's current beliefs and
expectations. These statements include, but are not limited to,
statements that relate to Spectrum’s business and its future,
including certain company milestones, Spectrum's ability to
identify, acquire, develop and commercialize a broad and diverse
pipeline of late-stage clinical and commercial products, the timing
and results of FDA decisions, and any statements that relate to the
intent, belief, plans or expectations of Spectrum or its
management, or that are not a statement of historical fact. Risks
that could cause actual results to differ include the possibility
that Spectrum’s existing and new drug candidates may not prove safe
or effective, the possibility that our existing and new
applications to the FDA and other regulatory agencies may not
receive approval in a timely manner or at all, the possibility that
our existing and new drug candidates, if approved, may not be more
effective, safer or more cost efficient than competing drugs, the
possibility that our efforts to acquire or in-license and develop
additional drug candidates may fail, our dependence on third
parties for clinical trials, manufacturing, distribution and
quality control and other risks that are described in further
detail in the company's reports filed with the Securities and
Exchange Commission. The company does not plan to update any such
forward-looking statements and expressly disclaims any duty to
update the information contained in this press release except as
required by law.
SPECTRUM PHARMACEUTICALS, INC.® and ROLONTIS® are registered
trademarks of Spectrum Pharmaceuticals, Inc. and its affiliate.
REDEFINING CANCER CARE™ and the Spectrum Pharmaceuticals logos are
trademarks owned by Spectrum Pharmaceuticals, Inc. Any other
trademarks are the property of their respective owners.
© 2020 Spectrum Pharmaceuticals, Inc. All Rights Reserved
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201204005066/en/
Robert Uhl Managing Director, Westwicke ICR 858.356.5932
robert.uhl@westwicke.com
Kurt Gustafson Chief Financial Officer 949.788.6700
InvestorRelations@sppirx.com
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Apr 2023 to Apr 2024